MSH2 and neoplasm: Specifically, tumor profiling with both panels ascertained the lack of clinically significant variants in 9 patients and the presence of 12 alterations in ATM, BRCA2, CTNNB1, MSH2, PIK3CA, PTEN and TP53 in 11 patients.